Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Liabilities and Shareholders Equity (2019 - 2023)

Historic Liabilities and Shareholders Equity for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $466.9 million.

  • ADC Therapeutics' Liabilities and Shareholders Equity fell 1219.71% to $466.9 million in Q3 2023 from the same period last year, while for Dec 2023 it was $1.4 billion, marking a year-over-year decrease of 3214.61%. This contributed to the annual value of $490.9 million for FY2022, which is 11.63% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Liabilities and Shareholders Equity is $466.9 million, which was down 1219.71% from $507.3 million recorded in Q2 2023.
  • ADC Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $638.0 million during Q3 2021, with a 5-year trough of $137682.0 in Q4 2019.
  • For the 5-year period, ADC Therapeutics' Liabilities and Shareholders Equity averaged around $401.7 million, with its median value being $479.3 million (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 12411985.76% in 2021, then crashed by 1962.82% in 2023.
  • ADC Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $137682.0 in 2019, then surged by 278.79% to $521526.0 in 2020, then soared by 94129.37% to $491.4 million in 2021, then dropped by 0.12% to $490.9 million in 2022, then dropped by 4.88% to $466.9 million in 2023.
  • Its Liabilities and Shareholders Equity was $466.9 million in Q3 2023, compared to $507.3 million in Q2 2023 and $467.7 million in Q1 2023.